Dr Ming Lee, RIO Trial Physician, appearance on the STI Podcast, IAS Conference Feedback 2023

After presenting at the 2023 HIV Cure & Immunotherapy Forum held alongside International AIDS Society (IAS) 2023, the 12th IAS Conference on HIV Science, in Brisbane, Dr Ming Lee was invited to appear on the Sexually Transmitted Infections (STI) Podcast. The episode, entitled IAS23 Conference Feedback in Brisbane, Australia in July 2023, discussed some of […]

Read More…

Dr Ming Lee (RIO Trial physician) talk on bNAbs in clinical trials at IAS 2023, Brisbane.

Our RIO Clinical Research Fellow at Imperial College London and Imperial College Healthcare NHS Trust, Dr Ming Lee, was invited to speak at the 2023 HIV Cure & Immunotherapy Forum held alongside International AIDS Society (IAS) 2023, the 12th IAS Conference on HIV Science, in Brisbane, Australia. The talk included an overview of the RIO […]

Read More…

RIO Trial featured in The Body’s review of HIV Research at the end of 2022

Dec. 21, 2022 by Tim Murphy “A T cell (red) that’s been infected with HIV produces many copies of the virus (blue), as shown in this colorized transmission electron micrograph. HIV cure research continues to seek out ways to end this process once and for all.” Photo: NIAID “It seems as though a day did […]

Read More…

RIO’s Prof Sarah Fidler featured in a news piece celebrating 25 years of Imperial’s Faculty of Medicine and trailblazing HIV and AIDS research

1st Dec 2022 by Genevieve Timmins, Imperial College London The launch of Imperial’s Faculty of Medicine in 1997 coincided with a new era in HIV/AIDS treatment and research. Just prior to its creation came the groundbreaking revelation that combining three antiretroviral drugs could drastically improve the prognosis of people living with HIV. The subsequent rollout […]

Read More…

Long-awaited results of the eCLEAR study are out showing the impact of the bNAb ‘3BNC117’ in people with detectable viraemia

17 Oct 2022, Nature Medicine The eCLEAR study published their results in Nature Medicine in October. This study combined the use of 3BNC117, which is a broadly neutralising antibody (bNAb), with a potent latency reversing agent, romidepsin, to reduce the HIV reservoir in individuals starting antiretroviral treatment (ART) for the first time. The study was […]

Read More…